Descriptive Analysis of KRAS and BRAF mutations in Senegalensis Patients with colorectal cancer
Diallo Agne F
Worldwide Colorectal cancer (CRC) is a leading cause to cancer mortality and morbidity. In many studies, mutations in the KRAS and BRAF genes are involved in colorectal cancer, and are associated with the primary resistance to the EGFR inhibitors. Objective of study is to investigate the prevalence of KRAS and BRAF mutations in first in Senegal and to correlate clinico-anatomical parameters according to genes mutation status in colorectal cancer. Genomic DNA from the tumor tissue was performed using the ReliaPrep gDNA Tissue kit from Promega on surgical specimens of twenty patients with colorectal cancer. The median age was 55 years and sex ratio was 0.82. Analysis of mutations in codons 12 and 13 of KRAS and in codon 600 of BRAF was assessed using High -resolution melting (HRM). Mutations were detected for KRAS in 45% and for BRAF in 55% of specimens and were not associated with clinico-anatomical parameters. Tumors harboring mutation in both KRAS and BRAF were observed in 15% of cases. The colon location of the tumor was the most recovered. Stage pT3 and pT4 were in more than ¾ of the cases and liver metastases had in two cases.
Share this article